Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK

Human Reproduction

Volumn 16, Issue 12, 2001, Pages 2563-2569

  Daya, S ^a   Ledger, W ^b   Auray, J P ^c   Duru, G ^c   Silverberg, K ^d   Wikland, M ^e   Bouzayen, R ^f   Howles, C M ^g,h   Beresniak, Ariel ^g,i  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c CNRS   (France)

^d Texas Fertility Center   (United States)

^e Carlanderska Hospital   (Sweden)

^f IWK HEALTH CENTRE   (Canada)

^g Serono International SA   (Switzerland)

^h International SA

ⁱ Serono International SA

Author keywords

Assisted reproduction; Cost effectiveness; Mathematical modelling; Recombinant FSH; Urinary FSH

Indexed keywords

RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; HUMAN; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; PREGNANCY; PROBABILITY; SIMULATION; SYSTEM ANALYSIS; UNITED KINGDOM; VALIDATION PROCESS;

EID: 0035652395     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.12.2563     Document Type: Article

References (23)

1. Recombinant human follicle stimulating hormone (r-FSH, Gonal-F) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques
2. An introduction to Markov modelling for economic evaluation
3. Patient-specific decisions about hormone replacement therapy in postmenopausal women
4. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
5. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach
6. Superovulation before IVF by recombinant versus urinary human FSH combined with a long GnRH analog protocol: A comparative study
7. Evaluation and treatment of the infertile couple
8. A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified FSH
9. A double-blind, randomized study to compare recombinant follicle stimulating hormone (FSH; Gonal-F®) with highly purified urinary FSH (Metrodin HP®) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists
10. The clinical efficacy of recombinant follicle stimulating hormone to the highly purified urinary preparation
11. Induction of superovulation in women undergoing assisted reproductive techniques: Recombinant human follicle stimulating hormone (rFSH; Gonal-F®) versus highly purified urinary FSH (Metrodin HP®)
12. Initial results from the comparison of recombinant FSH and urinary FSH in an IVF programme
13. Pharmaco-economic aspects of in-vitro fertilization in Italy
14. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France
15. A prospective, randomized assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon® versus Metrodin®) in in-vitro fertilization
16. Recombinant follicle-stimulating hormone (follitropin beta, Puregon®) yields higher pregnancy rates in in vitro fertilization than urinary gonadotrophins
17. A cost-effectiveness clinical decision analysis model for schizophrenia
18. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization
19. Assisted reproductive technology in the United States: 1990 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry
20. Economic evaluation of a recombinant follicle-stimulating hormone (Follitropin Beta, Puregon®) in infertile women undergoing in vitro fertilisation in Greece